Compare Citius Pharmaceuticals Inc (CTXR) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while T-Rex 2X Long MSTR Daily Target ETF trades at $1.81. The key difference: Citius Pharmaceuticals Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| CTXR | MSTU | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $76.30 |
52-Week Low | $0.48 | $1.46 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
MSTU, a leveraged ETF tracking MicroStrategy (MSTR), trades at $1.815, down 3.97% on the day, reflecting severe long-term erosion. The technical outlook is bearish with moving averages signaling strong selling pressure, while oscillators remain neutral. Recent news highlights catastrophic losses, including a 98% decline from 2024 levels, exacerbated by a 10:1 reverse stock split effective August 24, 2026.
The outlook for MSTU is highly risky due to leveraged decay and dependency on MSTR's volatile performance. Investment opportunities are minimal given the fund's history of value destruction, with risks including daily rebalancing losses, crypto market exposure, and lack of fundamental company metrics. Caution is paramount for potential investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
